   |
|
BASIC RESEARCH |
|
| Year : 2012 | Volume
: 57
| Issue : 1 | Page : 12-14 |
|
| Serum concentration of IL-6, IL-2, TNF-α, and IFNγ in Vitiligo patients |
|
|
Suman Singh1, Usha Singh1, SS Pandey2
1 Division of Immunopathology, Department of Pathology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India
2 Department of Dermatology, and Venereology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India
| Date of Web Publication | 10-Mar-2012 |
Correspondence Address:
Suman Singh
Division of Immunopathology, Department of Pathology, Institute of Medical Sciences, Banaras Hindu University, Varanasi-221 005
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0019-5154.92668
|
|
 Abstract | | |
Background: Vitiligo is an acquired depigmenting disorder characterized by the loss of functional melanocytes from the epidermis. Although the etiology of vitiligo is unknown, over the last few years, substantial data from clinical research has greatly supported the 'Autoimmune theory' and this is supported by the frequent association of vitiligo with disorders that have an autoimmune origin, including Hashimoto's thyroiditis, Graves disease, type 1 insulin-dependent diabetes mellitus, and Addison's disease. As cytokines are important mediators of immunity, there is evidence to suggest that they play a major role in the pathogenesis of autoimmune diseases. Aim: Keeping this in view we have assayed sera for cytokine IL-6, IL-2, Tumor necrosis factor (TNF)-α, and IFNγ in 80 cases of vitiligo and compared it with healthy subjects, in order to find out whether they play a role in the pathogenesis of vitiligo or not. Materials and Methods: Serum IL-6, IL-2, TNF-α, and IFNγ were done by the indirect enzyme linked immunosorbent assay (ELISA). Results: The mean serum IL-6 and IL-2 levels in the patient group were significantly higher when compared with those of the normal controls. The mean serum IFNγ level in patients with vitiligo was significantly lower than that in the control group. There was no significant difference in the serum level of TNF-α between vitiligo and healthy controls. Conclusion : An increase in the production of proinflammatory cytokines such as IL-6 and IL-2 in vitiligo patients may play an important role in melanocytic cytotoxicity. Thus, we speculate that the cytokine production of epidermal microenvironment may be involved in vitiligo.
Keywords: Cytokines, IFN-gamma, IL-2, IL-6, TNF-alpha, vitiligo
How to cite this article:
Singh S, Singh U, Pandey S S. Serum concentration of IL-6, IL-2, TNF-α, and IFNγ in Vitiligo patients. Indian J Dermatol 2012;57:12-4 |
How to cite this URL:
Singh S, Singh U, Pandey S S. Serum concentration of IL-6, IL-2, TNF-α, and IFNγ in Vitiligo patients. Indian J Dermatol [serial online] 2012 [cited 2023 Dec 9];57:12-4. Available from: https://www.e-ijd.org/text.asp?2012/57/1/12/92668 |
| Introduction | |  |
Vitiligo is an acquired depigmenting disorder, characterized by the loss of functional melanocytes from the epidermis. About one to two percent of the world's population suffers from this disorder, without any regard to ethnic, racial, or socioeconomic background. [1] Although the etiology of vitiligo is unknown, over the last few years, substantial data from the clinical research has greatly supported the 'Autoimmune theory' [2],[3] and this is supported by the frequent association of vitiligo with disorders that have an autoimmune origin including Hashimoto's thyroiditis, Graves disease, type 1 insulin-dependent diabetes mellitus, and Addison's disease. [4] As cytokines are important mediators of immunity and there are evidences to suggest that it plays a major role in the pathogenesis of autoimmune diseases including Hashimoto's thyroiditis [5] and insulin-dependent type-1 diabetes mellitus, [6] the alteration in the concentration of various cytokines such as IL-6, IL-8, IL-10, IL-2, TNF-α, and IFNγ have been the subject of intensive investigations in autoimmune disorders, [4],[5],[7],[8] but only a few studies dealt with alterations in the serum concentration of cytokines in vitiligo. Keeping this in view we have assayed sera for cytokine IL-6, IL-2, TNF-α, and IFNγ in 80 cases of vitiligo and compared it with that of healthy subjects, in order to find out whether or not they play a role in the pathogenesis of vitiligo. A total of 80 patients with vitiligo were taken from the Outpatient Department of Dermatology and Venereology of the Sir Sunderlal Hospital, B.H.U., Varanasi, for a period of nine months. About 50 healthy controls from the staff and students of the institute were included in the study with no present or past history of autoimmune or any systemic disease. Clinical diagnosis of the patients was done by the dermatologist. Blood samples were taken when the patients first visited the dermatologist. The study was approved by the ethical committee of this institute and consent was given by all the patients enrolled in the study.
| Materials and Methods | | |
Vitiligo patients included 49 cases (61.25%) of generalized vitiligo and 31cases (38.75%) of localized vitiligo. On the basis of stage, 44 cases (55%) were of stable stage (no change in the new lesions within the two months prior to the study, as observed by the patients) and 36 cases (45%) were of active stage (new lesions within the two months prior to the study, as observed by the patients). Exclusion criteria consisted of patients who had diabetes mellitus, thyroiditis, pernicious anemia, psoriasis, atopic dermatitis, and inflammatory skin diseases. The 80 patients included 48 (60%) males and 32 (40%) women.
Laboratory Analysis-serum IL-6, IL-2, TNF-α, and IFNγ were done by indirect enzyme-linked immunosorbent assay (ELISA), kit of Immunotech, a Beckman Coulter company of France, supplied by M/S OSB Agencies Delhi, India.
Statistical analysis
The statistical analysis of the data was done using the student's t-test for difference of mean, on SPSS for windows (version 16.0) statistical package (SPSS Inc., Chicago, IL) computer statistics program. P values less than 0.05 were taken as significant.
| Results | | |
The mean age of vitiligo patients and controls were 32.16±16.01 and 32.62±11.52 years, respectively. In vitiligo, the age of the patient varied from 10 to 65 years and in healthy volunteers from 19 to 60 years.
The mean serum IL-6 and IL-2 levels in the patient group were significantly higher when compared with that of the normal controls (13.21±8.79 vs. 5.62±2.25 pg/ml and 17.52±6.82 vs. 3.18±2.03 pg/ml, respectively, [Table 1] and [Table 2]).
There was a significant relationship in IFNγ between the vitiligo and control groups. The mean serum IFNγ level in patients with vitiligo was significantly lower than in the control group (0.17±0.08 vs. 0.26±0.05 IU/ml, [Table 3]).
The mean serum TNF-α concentration was increased in the patient group as compared to the control group (7.88±3.11 vs. 7.22±4.01, [Table 4]), but there was no significant difference between the means of the two groups. | Table 4: Serum concentration of Tumor necrosis factor á in vitiligo patients
Click here to view |
There was no significant difference in the serum level of IL-6, IL-2, TNF-α, and IFNγ between the active and stable cases of vitiligo. The mean IL-6 level was significantly elevated in patients with a duration of disease less than 15 years.
| Discussion | | |
In our study, the serum concentration of IL-6 was significantly elevated in the patients rather than in the controls. On further analysis it was found that IL-6 significantly increased in patients, in whom the duration of disease was more than 15 years. These results could be substantiated by the study of several workers on vitiligo cases. [9],[10],[11],[12] All these workers reported high IL-6 level in vitiligo patients. Il-6 was produced by mononuclear cells, which could induce the expression of ICAM-1 (intercellular cell adhesion molecules) on melanocytes, [13] which might then facilitate leukocyte-melanocyte interactions, leading to polyclonal B-cell activation and subsequently increasing autoantibody production, leading to immunological damage of the melanocytes. [14]
Another interesting finding in this study is a decrease in the production of IFNγ in vitiligo, which may explain the poor cell-mediated immunity in these cases to some unknown antigens.[15] Similar to us, other workers [11] also reported decreased IFNγ in vitiligo.
In our study, the serum concentration of TNF-α was increased in the vitiligo group, but statistically it was not significant. A weak, but existing relation between the serum levels and a possible intercutaneous role of TNF-α in vitiligo may be suggested. Similarly, Moretti et al., reported an increased TNF-α in the epidermis from vitiligo biopsies. [9],[16] TNF-α could contribute to keratinocyte apoptosis, which may result in autoimmune response and ultimately melanocyte disappearance.[15] It has also been reported that TNF-α leads to mitochondria-dependent cell death and activation of the inflammatory gene.[17] Contrary to this, Yu et al.[11] reported a significant decrease in TNF-α level in 12 non-segmental vitiligo patients.
According to our study, the mean value of serum IL-2 has been significantly increased in vitiligo cases as compared to the controls. IL-2 is primarily produced by recently activated T cells, which act as growth and death factors for antigen-activated T lymphocytes and also promote the development of T regulatory cells. [18]
The studies by Yeo et al.[19] and Galadari, [20] on 79 and 32 vitiligo patients, respectively, showed that the serum levels of sIL-R (soluble interleukin-2 receptor) were elevated in the patient group as compared to the controls. The sIL-2R was correlated with the amount of IL-2R expressed on the T cell, which in turn was stimulated by IL-2. [21],[22],[23]
| Conclusion | | |
An increase in the production of pro-inflammatory cytokines, such as IL-6 and IL-2, in vitiligo patients, may play an important role in melanocytic cytotoxicity. Thus, we speculate that the cytokine production of the epidermal microenvironment may be involved in vitiligo. Decreased concentration of IFNγ and a normal level of TNF-α suggest that probably TH1-mediated cell-mediated immunity is not involved in the pathogenesis of vitiligo; however, the rise of IL-2 cannot be explained. Further studies with a larger sample size are suggested, to elucidate these issues in future.
| References | | |
| 1. | Lerner AB. Vitiligo. J Invest Dermatol 1959;32:285-310. 
|
| 2. | Ongenae K, van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment cell Res 2003;16:90-100.
|
| 3. | van den Wijngaard R, Wankowicz Kalinska A, Pal S, Weening J, Das P. Autoimmune melanocyte destruction in vitiligo. Lab Invest 2001;81:1061-7.
|
| 4. | Alkahateeb A, Fain PR, Thody A, Bennett DC, Spritz RA. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res 2003;16:208-14.
|
| 5. | Paolieri F, Salmaso C, Battifora M, Montagna P, Pesce G, Bagnasco M. Possible pathogenetic relevance of interleukin-1â in 'destructive' organ-specific autoimmune disease (Hashimoto's thyroiditis). Ann New York Acad Sci 1999;876:221-8.
|
| 6. | Espersen GT, Mathiesen O, Grunnet N, Jensen S, Ditzel J. Cytokine plasma levels and lymphocyte subsets in patients with newly diagnosed insulin-dependent (type 1) diabetes mellitus before and following initial insulin treatment. APMIS 1993;101:703-6.
|
| 7. | Ko YC, Kawai T. Interleukin-8. Rinsho Byori 1995;43:329-34.
|
| 8. | Ajjan RA, Watson PF, McIntosh RS, Weetman AP. Intrathyroidal cytokine gene expression in Hashimoto's thyroiditis. Clin Exp Immunol 1996;105:523-8.
|
| 9. | Moretti S, Spallanzani A, Amato L, Hautmann G, Gallerani I, Fabiani M, et al. New insights into the pathogenesis of vitiligo: Imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res 2002;15:87-92.
|
| 10. | Pichler R, Sfetsos K, Badics B, Gutenbrunner S, Berg J, Auböck J. Lymphocyte imbalance in vitiligo patients indicated by elevated CD4C/CD8C T-cell ratio. Wien Med Wochenschr 2009;159:337-41.
|
| 11. | Yu HS, Chang KL, Yu CL, Li HF, Wu MT, Wu CS, et al. Alterations in IL-6, IL-8, GM-CSF, TNF-alpha, and IFN-gamma release by peripheral mononuclear cells in patients with active vitiligo. J Invest Dermatol 1997;108:527-9.
|
| 12. | Zailaie MZ. Decreased proinflammatory cytokine production by peripheral blood mononuclear cells from vitiligo patients following aspirin treatment. Saudi Med J 2005;26:799-805.
|
| 13. | Kirnbauer R, Charvat B, Schauer K, Kock A, Urbanshi A, Forster E, et al. Modulation of intercellular adhesion molecule-1 expression on human melanocytes and melanoma cells: Evidence for a regulatory role of IL-6, IL-7, TNF-á and UVB light. J Invest Dermatol 1992;98:320-6.
|
| 14. | Morelli JG, Norris DA. Influence of inflammatory mediators and cytokines on human melanocyte function. J Invest Dermatol 1993;100:191-5.
|
| 15. | Kao CH, Yu HS. Depletion and repopulation of Langerhans cells in non-segmental type vitiligo. J Dermatol 1990;17:287-96.
|
| 16. | Moretti S, Fabbri P, Baroni G, Berti S, Bani D, Berti E, et al. Keratinocyte dysfunction in vitiligo epidermis: Cytokine microenvironment and correlation to keratinocyte apoptosis. Histol Histopathol 2009;24:849-57.
|
| 17. | Wankowicz-Kalinska A, van Den Wijngaard RM, Tigges BJ, Westerhof W, Ogg GS, Cerundolo V, et al. Immunopolarization of CD4 + and Cd8+T cells to type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest 2003;83:683-95.
|
| 18. | Malek TR. The main function of IL-2 is to promote the development of T regulatory cells. J Leukoc Biol 2003;74:961-5.
|
| 19. | Yeo UC, Yang YS, Park KB, Sung HT, Jung SY, Lee ES, et al. Serum concentration of the soluble interleukin-2 receptor in vitiligo patients. J Dermatol Sci 1999;19:182-8.
|
| 20. | Galadari I. Serum levels of the soluble interleukin-2 receptor in vitiligo patients in UAE. Eur Ann Allergy Clin Immunol 2005;37:109-11.
|
| 21. | Goldsmith MA, Greene WC. Interleukin-2 and the interleukin-2 receptor. In: Thomson A, editor. The Cytokine Handbook, 2 nd ed. London: Academic Press; 1994. p. 55-80
|
| 22. | Gaulton GN, Williamson P. Interleukin-2 and the interleukin-2 receptor complex. Chem Immunol 1994;59:91-114.
|
| 23. | Rubin LA, Nelson DL. The soluble interleukin-2 receptor: Biology, function, and clinical application. Ann Intern Med 1990;113:619-27.
|
[Table 1], [Table 2], [Table 3], [Table 4] |
|
| This article has been cited by | | 1 |
Does immune dysregulation contribute towards development of hypopigmentation in Indian post kala-azar dermal leishmaniasis? |
|
| Ritika Sengupta, Sneha Mitra, Aishwarya Dighal, Srija Moulik, Surya Jyati Chaudhuri, Nilay Kanti Das, Uttara Chatterjee, Mitali Chatterjee | | Experimental Dermatology. 2023; | | [Pubmed] | [DOI] | | | 2 |
Improvements in immune/melanocyte biomarkers with JAK3/TEC family kinase inhibitor ritlecitinib in vitiligo |
|
| Emma Guttman-Yassky, Ester Del Duca, Joel Correa Da Rosa, Jonathan Bar, Khaled Ezzedine, Zhan Ye, Wen He, Craig Hyde, Mina Hassan-Zahraee, Yuji Yamaguchi, Elena Peeva | | Journal of Allergy and Clinical Immunology. 2023; | | [Pubmed] | [DOI] | | | 3 |
A Hospital-Based Case-Control Study on Raised Homocysteine Level in Vitiligo Patients and Its Association With Disease Severity |
|
| Nidhi Choudhary, Narendra S Patel, Ajay S Raghuwanshi, Nishant Choudhary, Surbhi Agrawal | | Cureus. 2023; | | [Pubmed] | [DOI] | | | 4 |
Vitiligo: Correlation with cytokine profiles and its role in novel therapeutic strategies: A case–control study |
|
| Karishma Desai, HariKishan Kumar, S Naveen, Prabhakar Somanna | | Indian Dermatology Online Journal. 2023; 14(3): 361 | | [Pubmed] | [DOI] | | | 5 |
Serum interleukin-6 and high sensitivity c-reactive protein levels and their correlation with the vitiligo disease activity and extent: A cross-sectional study of 58 patients |
|
| Bhargavi M Uttmani, Keshavmurthy A Adya, Arun C Inamadar | | Journal of Cutaneous and Aesthetic Surgery. 2023; | | [Pubmed] | [DOI] | | | 6 |
Clinical and pathogenetic justification of the use of azathioprine in the treatment of progressive non-segmental vitiligo |
|
| Kseniia A. Vovdenko, Olga Yu. Olisova, Konstantin V. Smirnov, Daria A. Svistunova, Konstantin M. Lomonosov | | Russian Journal of Skin and Venereal Diseases. 2023; 26(4): 339 | | [Pubmed] | [DOI] | | | 7 |
Association Among MIF, IFIH1, and IL6 Gene Polymorphisms and Non-Segmental Vitiligo in a Chinese Han Population |
|
| Danfeng Wang, Shuhui Min, Xiao Lin, Guan Jiang | | Clinical, Cosmetic and Investigational Dermatology. 2022; Volume 15: 1597 | | [Pubmed] | [DOI] | | | 8 |
Patho-immunological mechanisms of vitiligo: the role of the innate and adaptive immunities and environmental stress factors |
|
| Safa Faraj, Elizabeth Helen Kemp, David John Gawkrodger | | Clinical and Experimental Immunology. 2022; 207(1): 27 | | [Pubmed] | [DOI] | | | 9 |
Evaluation of the association between platelet tests and thyroid-stimulating hormone levels in patients with vitiligo |
|
| Gülhan Aksoy Saraç, Saadet Ibis, Turan Akdag | | Journal of Cosmetic Dermatology. 2022; | | [Pubmed] | [DOI] | | | 10 |
The role of cytokines and vitamin D in vitiligo pathogenesis |
|
| Amir Mohammad Beyzaee, Mohamad Goldust, Anant Patil, Ghasem Rahmatpour Rokni, Samira Beyzaee | | Journal of Cosmetic Dermatology. 2022; | | [Pubmed] | [DOI] | | | 11 |
Evaluation of plasma zonulin level and its relationship with inflammatory cytokines in patients with vitiligo |
|
| Selami Arslan, Nihal Altunisik, Dursun Turkmen, Muhammed M. Uremis, Serpil Sener, Yusuf Turkoz | | Journal of Cosmetic Dermatology. 2022; | | [Pubmed] | [DOI] | | | 12 |
Biomarkers and clinical indicators of disease activity in vitiligo |
|
| Liesbeth Delbaere, Reinhart Speeckaert, Sandrine Herbelet, Arno Belpaire, Jolien Duponselle, Nanja van Geel | | Dermatological Reviews. 2022; | | [Pubmed] | [DOI] | | | 13 |
Catecholamines’ accumulation and their disturbed metabolism at perilesional site: a possible cause of vitiligo progression |
|
| Sushma Tanwar, Vishal Thakur, Alka Bhatia, Davinder Parsad | | Archives of Dermatological Research. 2022; | | [Pubmed] | [DOI] | | | 14 |
Dendritic cells and their associated pro-inflammatory cytokines augment to the inflammatory milieu in vitiligo skin |
|
| Ashu Singh, Dayasagar Das, Santosh Kurra, Sudheer Arava, Somesh Gupta, Alpana Sharma | | Cytokine. 2021; 148: 155598 | | [Pubmed] | [DOI] | | | 15 |
Immune-modulatory effects of lenalidomide inhibited the progression of lesions in a vitiligo mouse model |
|
| Naveed Pervaiz, Harjot Kaur, Davinder Parsad, Ravinder Kumar | | Pigment Cell & Melanoma Research. 2021; 34(5): 918 | | [Pubmed] | [DOI] | | | 16 |
Prolactin and vitiligo: proposed autocrine/paracrine actions |
|
| GhadaM El-Hanafy, OlfatG Shaker, Aya Ihab, HebaA Abdelkader | | Journal of the Egyptian Women's Dermatologic Society. 2021; 18(1): 61 | | [Pubmed] | [DOI] | | | 17 |
Multifactorial expression of IL-6 with update on COVID-19 and the therapeutic strategies of its blockade (Review) |
|
| Elena Niculet, Valentin Chioncel, Alina Elisei, Magdalena Miulescu, Olimpia Buzia, Lawrence Nwabudike, Mihaela Craescu, Miruna Draganescu, Florin Bujoreanu, Elisabeta Marinescu, Manuela Arbune, Diana Radaschin, Carmen Bobeica, Aurel Nechita, Alin Tatu | | Experimental and Therapeutic Medicine. 2021; 21(3) | | [Pubmed] | [DOI] | | | 18 |
VITILIGO TANILI HASTALARDA INTERFERON-GAMMA/ INTERLÖKIN-10 ORANININ HASTALIK AKTIVITESI VE YAYGINLIG?I ILE ILIS¸KISI |
|
| Gözde Emel GÖKÇEK, Eda ÖKSÜM, Demet KARTAL, Murat BORLU, Salih Levent ÇINAR | | Bozok Tip Dergisi. 2020; | | [Pubmed] | [DOI] | | | 19 |
Association Analysis of Tumor Necrosis Factor Alpha Promoter Polymorphisms and Vitiligo Susceptibility in South Indian Tamils |
|
| Kalai Selvi Rajendiran, Medha Rajappa, Laxmisha Chandrashekar, Devinder Mohan Thappa, Panneer Devaraju | | Dermatology. 2020; 236(6): 554 | | [Pubmed] | [DOI] | | | 20 |
Tumor necrosis factor (TNF)-a- 308 G/A gene polymorphism (rs1800629) in Egyptian patients with alopecia areata and vitiligo, a laboratory and in silico analysis |
|
| Talal Abd El-Raheem, Rania H. Mahmoud, Enas M. Hefzy, Mohamed Masoud, Reham Ismail, Nesreen M. M. Aboraia, Mauro Picardo | | PLOS ONE. 2020; 15(12): e0240221 | | [Pubmed] | [DOI] | | | 21 |
Effect of TNF-a -308G/A (rs1800629) Promoter Polymorphism on the Serum Level of TNF-a Among Iraqi Patients with Generalized Vitiligo |
|
| Ronak Ahmed, Dana Sharif, Mohammad Jaf, Dashty Mohammed Amin | | Clinical, Cosmetic and Investigational Dermatology. 2020; Volume 13: 825 | | [Pubmed] | [DOI] | | | 22 |
Case Series: Gene Expression Analysis in Canine Vogt-Koyanagi-Harada/Uveodermatologic Syndrome and Vitiligo Reveals Conserved Immunopathogenesis Pathways Between Dog and Human Autoimmune Pigmentary Disorders |
|
| Ista A. Egbeto, Colton J. Garelli, Cesar Piedra-Mora, Neil B. Wong, Clement N. David, Nicholas A. Robinson, Jillian M. Richmond | | Frontiers in Immunology. 2020; 11 | | [Pubmed] | [DOI] | | | 23 |
Osteoporosis in Skin Diseases |
|
| Maria Maddalena Sirufo, Francesca De Pietro, Enrica Maria Bassino, Lia Ginaldi, Massimo De Martinis | | International Journal of Molecular Sciences. 2020; 21(13): 4749 | | [Pubmed] | [DOI] | | | 24 |
Increased Serum Levels of IFN-?, IL-1ß, and IL-6 in Patients with Alopecia Areata and Nonsegmental Vitiligo |
|
| Katarzyna Tomaszewska, Magdalena Kozlowska, Andrzej Kaszuba, Aleksandra Lesiak, Joanna Narbutt, Anna Zalewska-Janowska | | Oxidative Medicine and Cellular Longevity. 2020; 2020: 1 | | [Pubmed] | [DOI] | | | 25 |
Altered expression of nuclear factor of activated T cells, forkhead box P3, and immune-suppressive genes in regulatory T cells of generalized vitiligo patients |
|
| Prashant S. Giri, Mitesh Dwivedi, Naresh C. Laddha, Rasheedunnisa Begum, Ankit H. Bharti | | Pigment Cell & Melanoma Research. 2020; 33(4): 566 | | [Pubmed] | [DOI] | | | 26 |
Investigation of the Role of Interleukin 6 in Vitiligo Pathogenesis |
|
| Mala Singh, Shahnawaz D. Jadeja, Jayvadan Vaishnav, Mohmmad Shoab Mansuri, Chandni Shah, Jay M. Mayatra, Atul Shah, Rasheedunnisa Begum | | Immunological Investigations. 2020; : 1 | | [Pubmed] | [DOI] | | | 27 |
Levels of TNF-a, IL-6, IL-17, IL-37 cytokines in patients with active vitiligo |
|
| Ebru Karagün, Sevim Baysak | | The Aging Male. 2020; 23(5): 1487 | | [Pubmed] | [DOI] | | | 28 |
Decreased levels of interleukin 27 in the serum of vitiligo patients |
|
| Saeed Malek Hosseini, Naser Gholijani, Nooshafarin Chenari, Kurosh Kalantar | | Anais Brasileiros de Dermatologia. 2020; 95(5): 570 | | [Pubmed] | [DOI] | | | 29 |
Cytokine profile (IL-2, IL-6, IL-17, IL-22, and TNF-a) in vitiligo—New insight into pathogenesis of disease |
|
| Sushama Sushama, Niharika Dixit, Ram Krishna Gautam, Pooja Arora, Ananta Khurana, Anubhuti Anubhuti | | Journal of Cosmetic Dermatology. 2019; 18(1): 337 | | [Pubmed] | [DOI] | | | 30 |
CXCL-10 and Interleukin-6 are reliable serum markers for vitiligo activity: A multicenter cross-sectional study |
|
| Marwa Abdallah, Medhat El-Mofty, Tag Anbar, Hoda Rasheed, Samia Esmat, Amira Al-Tawdy, Marwa M. Fawzy, Dalia Abdel-Halim, Rehab Hegazy, Heba Gawdat, Dalia Bassiouny, Mona A. Ibrahim, Iman Sany, Mahy El-Bassiouny, Mohamed Khalil, Abeer Abdel-Aziz, Zeinab M. El Maadawi, Wedad Z. Mostafa | | Pigment Cell & Melanoma Research. 2018; 31(2): 330 | | [Pubmed] | [DOI] | | | 31 |
Ameliorative effects of fruit stem extract from Muscat Bailey A against chronic UV-induced skin damage in BALB/c mice |
|
| Byoung Ok Cho, Denis Nchang Che, Jae Young Shin, Hyun Ju Kang, Seon Il Jang | | Biomedicine & Pharmacotherapy. 2018; 97: 1680 | | [Pubmed] | [DOI] | | | 32 |
The role of interleukins in vitiligo: a systematic review |
|
| I.A. Gomes, F.O. de Carvalho, A.F. de Menezes, F.M. Almeida, S. Shanmugam, J. de Souza Siqueira Quintans, L.J. Quintans-Júnior, T.R. de Moura, P.D. Oliveira, A.A. de Souza Araújo | | Journal of the European Academy of Dermatology and Venereology. 2018; 32(12): 2097 | | [Pubmed] | [DOI] | | | 33 |
Serum Levels of Interleukin-2 in Patients with Alopecia Areata: Relationship with Clinical Type and Duration of the Disease |
|
| Emina Kasumagic-Halilovic, Semra Cavaljuga, Nermina Ovcina-Kurtovic, Lamija Zecevic | | Skin Appendage Disorders. 2018; 4(4): 286 | | [Pubmed] | [DOI] | | | 34 |
Cellular stress and innate inflammation in organ-specific autoimmunity: lessons learned from vitiligo |
|
| John E. Harris | | Immunological Reviews. 2016; 269(1): 11 | | [Pubmed] | [DOI] | | | 35 |
Expression levels and genetic polymorphisms of interleukin-2 and interleukin-10 as biomarkers of Gravesæ disease |
|
| Cuige Liang,Wenhua Du,Qingyu Dong,Xiaomeng Liu,Wenxia Li,Yueli Wang,Guanqi Gao | | Experimental and Therapeutic Medicine. 2015; | | [Pubmed] | [DOI] | | | 36 |
Increased circulating Th17 cells and elevated serum levels of TGF-beta and IL-21 are correlated with human non-segmental vitiligo development |
|
| Li Zhou,Yu-Ling Shi,Kai Li,Iltefat Hamzavi,Tian-Wen Gao,Richard H. Huggins,Henry W. Lim,Qing-Sheng Mi | | Pigment Cell & Melanoma Research. 2015; : n/a | | [Pubmed] | [DOI] | | | 37 |
A Randomized Comparative Study of Oral Corticosteroid Minipulse and Low-Dose Oral Methotrexate in the Treatment of Unstable Vitiligo |
|
| Harsimer Singh, Muthu Sendhil Kumaran, Anupama Bains, Davinder Parsad | | Dermatology. 2015; 231(3): 286 | | [Pubmed] | [DOI] | | | 38 |
Recent advances in childhood vitiligo |
|
| Nanette B. Silverberg | | Clinics in Dermatology. 2014; | | [Pubmed] | [DOI] | | | 39 |
Pediatric Vitiligo |
|
| Nanette B. Silverberg | | Pediatric Clinics of North America. 2014; | | [Pubmed] | [DOI] | | | 40 |
The combination of tumour necrosis factor-a -308A and interleukin-10 -1082G gene polymorphisms and increased serum levels of related cytokines: susceptibility to vitiligo |
|
| I. E. Aydingöz,M. Kanmaz-Özer,A. Gedikbasi,P. Vural,S. Dogru-Abbasoglu,M. Uysal | | Clinical and Experimental Dermatology. 2014; : n/a | | [Pubmed] | [DOI] | | | 41 |
T helper and regulatory T cell cytokine profile in active, stable and narrow band ultraviolet B treated generalized vitiligo |
|
| Manoj Kumar Tembhre,Vinod Kumar Sharma,Alpana Sharma,Parthaprasad Chattopadhyay,Somesh Gupta | | Clinica Chimica Acta. 2013; 424: 27 | | [Pubmed] | [DOI] | | | 42 |
Decreased regulatory T-cells and CD4+/CD8+ratio correlate with disease onset and progression in patients with generalized vitiligo |
|
| Mitesh Dwivedi,Naresh C. Laddha,Prateek Arora,Yogesh S. Marfatia,Rasheedunnisa Begum | | Pigment Cell & Melanoma Research. 2013; 26(4): 586 | | [Pubmed] | [DOI] | | | 43 |
A Quantitative Increase in Regulatory T Cells Controls Development of Vitiligo |
|
| Shilpak Chatterjee,Jonathan M Eby,Amir A Al-Khami,Myroslawa Soloshchenko,Hee-Kap Kang,Navtej Kaur,Osama S Naga,Anuradha Murali,Michael I Nishimura,I Caroline Le Poole,Shikhar Mehrotra | | Journal of Investigative Dermatology. 2013; | | [Pubmed] | [DOI] | | | 44 |
The Role of Tumor Necrosis Factor-a in the Pathogenesis of Vitiligo |
|
| Carlos R. Camara-Lemarroy,Julio C. Salas-Alanis | | American Journal of Clinical Dermatology. 2013; 14(5): 343 | | [Pubmed] | [DOI] | | | 45 |
Evaluation of a standardized extract of Ginkgo biloba in vitiligo remedy |
|
| Abu-Raghif, A.R., Ali, N.M., Farhood, I.G., Hameed, M.F., Sahib, H.B. | | Source of the Document Asian Journal of Pharmaceutical and Clinical Research. 2013; | | [Pubmed] | | | 46 |
Potential advantages of simvastatin as a novel anti-vitiligo arsenal |
|
| Feily, A., Baktash, D., Mohebbipour, A. | | European Review for Medical and Pharmacological Sciences. 2013; | | [Pubmed] | |
|
|
|
|
|
|
|
|
|
|
|
| Article Access Statistics | | | Viewed | 8609 | | | Printed | 296 | | | Emailed | 1 | | | PDF Downloaded | 176 | | | Comments | [Add] | | | Cited by others | 46 | | |
|
|
